Evidence-based decision making for vaccines: The need for an ethical foundation

Vaccine

Volumn 30, Issue 6, 2012, Pages 1009-1013

  Field, Robert I ^a   Caplan, Arthur L ^b  

^a DREXEL UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cost effectiveness; Decision making; Ethics; Evidence based; Policy

Indexed keywords

VACCINE;

ARTICLE; BENEFICENCE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE QUALITY; HUMAN; MEDICAL ETHICS; PATIENT AUTONOMY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; VACCINATION;

DECISION MAKING; HUMANS; UNITED STATES; VACCINATION; VACCINES;

EID: 84856316124     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.053     Document Type: Article

References (40)

1. Fielding J.E., Teutsch S.M. An opportunity map for societal investment in health. JAMA 2011, 305(20):2110-2111.
2. Muenning P.A., Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001, 33(11):1879-1885.
3. Poland G.A., Marcuse E.K. Developing vaccine policy: attributes of just policy and a proposed template to guide decision and policy making. Vaccine 2011, 29(44):7577-7578.
4. Andrus J.K., Jauregui B., De Oliveira L.H., Ruiz C. Challenges to building capacity for evidence-based new vaccine policy in developing countries. Health Aff 2011, 30(6):1104-1111.
5. National Health Service. Vaccinations - your NHS guide to vaccinations for you and your family - the power of vaccines; 2010 [accessed 08.12.11]. http://www.nhs.uk/Planners/vaccinations/Pages/miracles.aspx.
6. Ehreth J. The global value of vaccination. Vaccine 2003, 21(7-8):596-600.
7. Owens D., Qaseem A., Choi R., Shekelle P. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 2011, 154(3):174-181.
8. Commission on Macroeconomics and Health Macroeconomics and health: investing in health for economic development 2001, World Health Organization, Geneva, Switzerland.
9. Patient protection and affordable care act; 2010.
10. World Health Organization WHO guide for standardization of economic evaluations of immunization programmes 2008, World Health Organization, Geneva, Switzerland.
11. Aylward R.B., Hull H.F., Cochi S.L., Sutter R.W., Olive J.-M., Melgaard B. Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ 2000, 78(3):285-297.
12. Meissner H.C., Strebel P.M., Orenstein W.A. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004, 114(4):1065-1069.
13. Caplan A. Is disease eradication ethical. Lancet 2009, 373:2192-2193.
14. Bill and Melinda Gates Foundation. Decade of vaccines; 2011 [accessed 08.12.11]. http://www.gatesfoundation.org/vaccines/Pages/decade-of-vaccines.aspx.
15. Shillcutt S.D., Walker D.G., Goodman C.A., Mills A.J. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009, 27(11):903-917.
16. Stack M.I., Ozawa S.I., Bishai D.M., Mirelman A., Tam Y., Niessen L., et al. Estimated economic benefits during the 'Decade of Vaccines' include treatment savings, gains in labor productivity. Health Aff 2011, 30(6):1021-1028.
17. Strong K., Mathers C., Leeder S., Beaglehole R. Preventing chronic disease: how many lives can we save?. Lancet 2005, 366(1578-1582):1578.
18. Whitehead S.J., Ali S. Health outcomes in economic evaluation: the QALY and utilities. BMJ 2010, 96:5-21.
19. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006, 21(5):402-408.
20. Reese P.P., Caplan A.L., Bloom R.D., Abt P.L., Karlawish J.H. How should we use age to ration health care? Lessons from the case of kidney transplantation. J Am Geriatr Soc 2010, 58(10):1980-1986.
21. Robberstad B. QALYs vs DALYs vs LYs gained: what are the differences, and what difference do they make for health care priority setting?. Norsk Epidemiologi 2005, 15(2):183-191.
22. Buyx A., Friedrich D., Shone-Siefert B. Rationing by clinical effectiveness. BMJ 2011, 342:531-533.
23. Baker R., Chilton S., Donaldson C., Jones-Lee M., Lancsar E., Mason H., et al. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law 2011, 6:435-447.
24. Li M., Vietri J., Galvani A.P., Chapman G.B. How do people value life?. Psychol Sci 2010, 21(2):163-167.
25. Persad G., Wertheimer A., Emanuel E.J. Principles for allocation of scarce medical interventions. Lancet 2009, 373:423-431.
26. Beauchamp T.L., Childress J.F. Principles of biomedical ethics 2001, Oxford University Press, New York. 5th ed.
27. Ozawa S.I., Stack M.L., Bishai D.M., Mirelman A., Friberg I.K., Niessen L., et al. During the 'Decade of Vaccines,' the lives of 6.4 million children valued at $231 billion could be saved. Health Aff 2011, 30(6):1010-1020.
28. LaForce F.M., Okwo-Bele J. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff 2011, 30(6):1049-1057.
29. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-396.
30. Medecins Sans Frontieres Full prescription: better malaria treatment for more people, MSF's experience 2008, Medecins Sans Frontieres, Brussels, Belgium.
31. Dawson A. The moral case for the routine vaccination of children in developed and developing countries. Health Aff 2011, 30(6):1029-1033.
32. Kennedy A., LaVail K., Nowak G., Basket M., Landry S. Confidence about vaccines in the United States: understanding parents' perceptions. Health Aff 2011, 30(6):1151-1159.
33. Gerber A.S., Patashnik E.M., Doherty D., Dowling D. A national survey reveals public skepticism about research-based treatment guidelines. Health Aff 2010, 29(10):1882-1884.
34. Hitt E. ACIP Recommends Meningococcal Booster Dose. Medscape Medical News; October 28, 2010. [accessed 08.12.11]. http://www.medscape.com/viewarticle/731392.
35. Caplan A.L. Will evidence ever be sufficient to resolve the challenge of cost-containment?. J Clin Oncol 2011, 29(15):1946-1948.
36. Smith J.C. The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP). Vaccine 2010, 28S:A68-A75.
37. Integrated Regional Information Networks. Nigeria: jail threat for polio vaccination refuseniks; August 16, 2011. [accessed 08.12.11]. http://www.unhcr.org/refworld/docid/4e4a66e3d.html.
38. Hotez P. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff 2011, 30(6):1080-1087.
39. Faden R.R., Chalkidou K. Determining the value of drugs - the evolving British experience. N Engl J Med 2011, 364(14):1289-1291.
40. Smith J.C., Snider D.E., Pickering L.K. Immunization policy development in the United States: the role of the Advisory Committee on Immunization Practices. Ann Intern Med 2009, 150(1):45-49.